🏛️ Verified NIH Record • Updated 2026-07-07
Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas (NCT06300528)
PERFORM: A Phase II Study of Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: University of Utah
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this clinical trial is to learn if the study drug pemigatinib is effective in treating patients with relapsed or refractory B-cell non-Hodgkin lymphomas.
Who can join: Review the eligibility criteria below.
Location: Huntsman Cancer Institute at University of Utah — Salt Lake City, Utah
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Huntsman Cancer Institute at University of Utah — Salt Lake City, Utah
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Explore by condition: All Relapsed or Refractory B-cell Non-Hodgkin Lymphoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.